Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models
ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment
On track to file an investigational new drug (IND) application for ADI-270 in 2Q 2024
Preclinical data will be featured in oral presentation on May 10, 2024
REDWOOD CITY, CA & BOSTON, MA, USA I April 22, 2024 I Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the ASGCT 27th Annual Meeting taking place from May 7-11, 2024, in Baltimore, MD. The oral presentation will take place on May 10, 2024 in the Targeted Gene and Cell Therapy session, co-chaired by Adicet Bio’s Chief Scientific Officer, Blake Aftab, Ph.D.
“We look forward to sharing new preclinical data at ASGCT further illustrating ADI-270’s robust anti-tumor activity with a differentiated method for targeting CD70 across multiple solid and hematologic cancers,” said Blake Aftab, Ph.D., Chief Scientific Officer of Adicet Bio. “ADI-270 is a next-generation CAR T cell therapy candidate designed to capitalize on potent tumor infiltration associated with the gamma delta T cell platform. ADI-270 is further enhanced with armoring to address suppressive tumor microenvironments and to address clearance by host T cells. In preclinical studies, ADI-270 demonstrated enhanced functional persistence and potency, including unique contribution of innate anti-tumor immunity, compared to multiple clinically relevant benchmarks in cancers expressing CD70. Supported by these encouraging data, we look forward to advancing ADI-270’s clinical development and remain on track to file an IND in renal cell carcinoma this quarter.”
Findings from this study have further characterized and have provided comparative benchmarking for the mechanisms by which ADI-270 provides enhanced functionality and potency in CD70 positive expressing tumors such as clear cell renal cell carcinoma (ccRCC) and facilitates a robust anti-tumor effect that supports its continued development. The preclinical findings indicate:
- ADI-270 demonstrated potent in vitro cytotoxicity against multiple CD70 positive tumor cell lines expressing varying levels of CD70.
- ADI-270 demonstrated robust cytotoxicity against heterogeneous CD70 negative and CD70 positive tumor cell cultures, highlighting the potential of gamma delta CAR T cells to be effective against tumors with mixed antigen expression.
- ADI-270’s unique use of CD27-based targeting of CD70 demonstrated robust CAR-mediated killing in multiple cancer models including ccRCC, non-small cell lung cancer and T cell lymphoma, and including those models with lower levels of CD70 expression.
- ADI-270 inhibited tumor growth in the context of suppressive tumor microenvironment attributed to inclusion of dominant-negative transforming growth factor beta receptor and demonstrated resilience to clearance by host T cells attributed to the function of CD27-based CAR targeting of CD70 also expressed on host T cells.
- Robust anti-tumor effects in an in vivo model of ccRCC, such as tumor infiltration, proliferation, and effector function, were observed after administration, resulting in eradication of CD70 positive tumor cells.
Details for the oral presentation are as follows:
Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Oral Session: Targeted Gene and Cell Therapy Session I
Presenting Author: Shon Green, Ph.D.
Date & Time: May 10, 2024 at 5:00 PM EST
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
SOURCE: Adicet Bio
Post Views: 1,597
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models
ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment
On track to file an investigational new drug (IND) application for ADI-270 in 2Q 2024
Preclinical data will be featured in oral presentation on May 10, 2024
REDWOOD CITY, CA & BOSTON, MA, USA I April 22, 2024 I Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the ASGCT 27th Annual Meeting taking place from May 7-11, 2024, in Baltimore, MD. The oral presentation will take place on May 10, 2024 in the Targeted Gene and Cell Therapy session, co-chaired by Adicet Bio’s Chief Scientific Officer, Blake Aftab, Ph.D.
“We look forward to sharing new preclinical data at ASGCT further illustrating ADI-270’s robust anti-tumor activity with a differentiated method for targeting CD70 across multiple solid and hematologic cancers,” said Blake Aftab, Ph.D., Chief Scientific Officer of Adicet Bio. “ADI-270 is a next-generation CAR T cell therapy candidate designed to capitalize on potent tumor infiltration associated with the gamma delta T cell platform. ADI-270 is further enhanced with armoring to address suppressive tumor microenvironments and to address clearance by host T cells. In preclinical studies, ADI-270 demonstrated enhanced functional persistence and potency, including unique contribution of innate anti-tumor immunity, compared to multiple clinically relevant benchmarks in cancers expressing CD70. Supported by these encouraging data, we look forward to advancing ADI-270’s clinical development and remain on track to file an IND in renal cell carcinoma this quarter.”
Findings from this study have further characterized and have provided comparative benchmarking for the mechanisms by which ADI-270 provides enhanced functionality and potency in CD70 positive expressing tumors such as clear cell renal cell carcinoma (ccRCC) and facilitates a robust anti-tumor effect that supports its continued development. The preclinical findings indicate:
- ADI-270 demonstrated potent in vitro cytotoxicity against multiple CD70 positive tumor cell lines expressing varying levels of CD70.
- ADI-270 demonstrated robust cytotoxicity against heterogeneous CD70 negative and CD70 positive tumor cell cultures, highlighting the potential of gamma delta CAR T cells to be effective against tumors with mixed antigen expression.
- ADI-270’s unique use of CD27-based targeting of CD70 demonstrated robust CAR-mediated killing in multiple cancer models including ccRCC, non-small cell lung cancer and T cell lymphoma, and including those models with lower levels of CD70 expression.
- ADI-270 inhibited tumor growth in the context of suppressive tumor microenvironment attributed to inclusion of dominant-negative transforming growth factor beta receptor and demonstrated resilience to clearance by host T cells attributed to the function of CD27-based CAR targeting of CD70 also expressed on host T cells.
- Robust anti-tumor effects in an in vivo model of ccRCC, such as tumor infiltration, proliferation, and effector function, were observed after administration, resulting in eradication of CD70 positive tumor cells.
Details for the oral presentation are as follows:
Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Oral Session: Targeted Gene and Cell Therapy Session I
Presenting Author: Shon Green, Ph.D.
Date & Time: May 10, 2024 at 5:00 PM EST
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
SOURCE: Adicet Bio
Post Views: 1,597